98%
921
2 minutes
20
Testosterone, many steroidal androgens, and nonsteroidal ligands that bind to androgen receptor and exert tissue-specific transcriptional activity (selective androgen receptor modulators [SARMs]) are being developed as function-promoting therapies to treat functional limitations associated with aging and chronic diseases. This narrative review describes preclinical studies, mechanisms, and randomized trials of testosterone, other androgens, and nonsteroidal SARMs. Sex differences in muscle mass and strength and empiric use of anabolic steroids by athletes to increase muscularity and athletic performance provide supportive evidence of testosterone's anabolic effects. In randomized trials, testosterone treatment increases lean body mass, muscle strength, leg power, aerobic capacity, and self-reported mobility. These anabolic effects have been reported in healthy men, hypogonadal men, older men with mobility limitation and chronic diseases, menopausal women, and HIV-infected women with weight loss. Testosterone has not consistently improved walking speed. Testosterone treatment increases volumetric and areal bone mineral density, and estimated bone strength; improves sexual desire, erectile function, and sexual activity; modestly improves depressive symptoms; and corrects unexplained anemia in older men with low testosterone levels. Prior studies have not been of sufficient size or duration to determine testosterone's cardiovascular and prostate safety. The efficacy of testosterone in reducing physical limitations, fractures, falls, progression to diabetes, and correcting late-onset persistent depressive disorder remains to be established. Strategies to translate androgen-induced muscle mass and strength gains into functional improvements are needed. Future studies should evaluate the efficacy of combined administration of testosterone (or a SARM) plus multidimensional functional exercise to induce neuromuscular adaptations required for meaningful functional improvements.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272983 | PMC |
http://dx.doi.org/10.1093/gerona/glad027 | DOI Listing |
J Med Chem
September 2025
State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Resistance-conferring mutations in the androgen receptor (AR) ligand-binding pocket (LBP) compromise the effectiveness of clinically approved orthosteric AR antagonists. Targeting the dimerization interface pocket (DIP) of AR presents a promising therapeutic approach. In this study, we report the design and optimization of -(thiazol-2-yl) furanamide derivatives as novel AR DIP antagonists, among which was the most promising candidate.
View Article and Find Full Text PDFArch Toxicol
September 2025
Department of Toxicology, Faculty of Medicine, Collegium Medicum, Rzeszów University, Al. mjr. W. Kopisto 2a, 35-959, Rzeszow, Poland.
ACP-105 (CAS: 1048998-11-3) is a novel non-steroidal selective androgen receptor modulator (SARM), increasingly detected in anti-doping analyses, yet lacking a comprehensive ADME profile. This study provides the first integrative in silico characterization of ACP-105's ADME properties using seven independent methods (ADMETlab 3.0, ADMET Predictor 12.
View Article and Find Full Text PDFSci Total Environ
September 2025
Department of Orthopedics and Traumatology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan Province, China. Electronic address:
The objective of this research was to use a network toxicology approach to examine the possible toxicity of the cigarette toxicants nicotine and coal tar that cause osteoporosis (OP) as well as its molecular processes. We determined the primary chemical structures and 128 targets of action of tar and nicotine using the Swiss Target Prediction, NP-MRD, and PubChem databases. We discovered that genes including DNAJB1, CCDC8, LINC00888, ATP6V1G1, MPV17L2, PPCS, and TACC1 had a disease prognostic guiding value by LASSO analysis and differential analysis of GEO microarray data.
View Article and Find Full Text PDFClin Cancer Res
September 2025
University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Human Kallikrein 2 (KLK2) is a prostate cancer tissue specific protein that is regulated by androgen receptor (AR) signaling. KLK2 was not previously recognized as a therapeutic target as it is secreted. It has now been demonstrated that KLK2 is expressed on the cell surface and targetable by various methodologies.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Department of Breast Surgery, Weifang People's Hospital, Weifang, Shandong Province, People's Republic of China.
The presence of androgen receptor (AR) as a marker can be detected in all breast cancer subtypes, and it may provide information on treatment response and prognosis. This study aimed to examine the correlation between AR expression and treatment response in patients diagnosed with human epidermal growth factor receptor 2 (HER2) positive breast cancer who were undergoing neoadjuvant therapy (NAT). The evaluation included breast cancer patients who received NAT and underwent surgery at Weifang People's Hospital's Department of Breast Surgery between October 2019 and October 2022.
View Article and Find Full Text PDF